Short-term efficacy and safety of apatinib combined with chemoradiotherapy in treatment of NSCLC patients with brain metastases
10.3872/j.issn.1007-385x.2020.06.011
- VernacularTitle:阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性
- Author:
YIN Xue
1
;
HU Zongtao
1
;
XU Xiuli
1
;
ZHANG Wenkang
1
;
CUI Xiangli
1
;
GAO Shile
2
Author Information
1. Department of Radiotherapy, Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei 230031,Anhui, China
2. Fourth Department of Oncology, No.901 Hospital of PLAJoint Logistic Support Force, Hefei 230031,Anhui, China
- Publication Type:Clinical Trial
- From:
Chinese Journal of Cancer Biotherapy
2020;27(6):658-663
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To observe the short-term efficacy and safety of Apatinib combined with radiotherapy and concurrent docetaxel and cisplatin chemotherapy in driver-gene-negative non-small cell lung cancer (NSCLC) patients with brain metastases. Methods: A total of 72 NSCLC patients with brain metastases, who were treated in our hospital from June 2018 to June 2019, were enrolled in this study. The driver gene was proved to be negative by next generation sequencing (NGS). The patients were divided into control group (36 cases) and treatment group (36 cases) by Digital random grouping method.The control group received 2 cycles of chemotherapy with docetaxel and cisplatin and concurrent radiotherapy for brain metastases, and the treatment group was given Apatinib anti-angiogenic treatment based on the regimen in control group. Primary study endpoints: confirmed objective response rate (cORR) and disease control rate (DCR); Secondary study endpoints: progression-free survival (PFS), quality of life (QOL) score, serum carcinoembryonic antigen (CEA), vascular endothelial growth factor (VEGF), and incidence of adverse drug events (AE). Results: Compared with the control group, cORR and DCR in treatment group were significantly improved [41.67% (15/36) vs 33.33% (12/36), 80.56% (29/36) vs 69.44% (25/36), all P<0.05], the median PFS was significantly prolonged (5.9 vs 4.6 months, P<0.05), and serum CEA and VEGF levels were significantly reduced [(16.5±2.3) vs (22.9±3.7) ng/ml, (291.6±42.6) vs (479.3±50.2) ng/L, all P<0.05], while the QOL score was slightly increased, but the difference was not statistically significant [(69.5±8.5) points vs (64.1±7.3) points, P>0.05]. There was no statistically significant difference in the incidence of acute brain edema, gastrointestinal reaction, bone marrow suppression, and liver dysfunction between the two groups of patients (all P>0.05); however, the incidences of oral mucositis, hand-foot syndrome, hypertension and proteinuria in the treatment group were significantly higher than those in the control group (all P<0.05). Conclusion: The efficacy of Apatinib combined with radiochemotherapy in driver-negative NSCLC patients with brain metastases is significantly better than that of radiochemotherapy alone, and the adverse reactions can be controlled. It is worthy of clinical recommendation.
- Full text:20200611.pdf
